Selinexor: A first-in-class nuclear export inhibitor for management of multiply relapsed multiple myeloma Journal Article


Authors: Peterson, T. J.; Orozco, J.; Buege, M.
Article Title: Selinexor: A first-in-class nuclear export inhibitor for management of multiply relapsed multiple myeloma
Abstract: Objective: To review the pharmacology, pharmacokinetics, efficacy, and safety of selinexor for management of relapsed multiple myeloma (MM). Data Sources: A literature search was performed of PubMed and MEDLINE databases (January 1, 2000, to November 14, 2019), abstracts from the American Society of Hematology and the American Society of Clinical Oncology, and ongoing studies from US National Institutes of Health ClinicalTrials.gov. Queries were performed using key words selinexor, SINE, XPO1, and Xpovio. Study Selection/Data Extraction: Human and animal studies related to the pharmacology, pharmacokinetics, efficacy, and safety of selinexor were identified. Data Synthesis: Although numerous advances have been made in MM management, there remains an unmet need for treatment of heavily relapsed/refractory disease. Selinexor is a first-in-class selective inhibitor of nuclear export, which, through inhibition of exportin-1, causes accumulation of tumor suppressor proteins, reduction in oncoproteins, and apoptosis of plasma cells. Selinexor exhibited an overall response in 26% of patients with multiply relapsed MM. Median progression-free survival was 3.7 months, and overall survival was 8.6 months. Common adverse effects include thrombocytopenia, neutropenia, fatigue, and nausea. Ongoing studies are investigating combination therapies utilizing selinexor. Relevance to Patient Care and Clinical Practice: This review describes the efficacy, safety, and clinical applicability of selinexor, a novel agent with potential to meet an unmet need in refractory MM. Conclusion: Selinexor has demonstrated activity in a heavily refractory patient population. Given the adverse effect profile and associated costs, additional studies are needed to further elucidate the appropriate clinical scenario and combinations for selinexor use. © The Author(s) 2019.
Keywords: treatment outcome; treatment response; oncoprotein; overall survival; fatigue; neutropenia; review; diarrhea; drug efficacy; drug safety; nonhuman; side effect; anorexia; clinical practice; progression free survival; apoptosis; bortezomib; multiple myeloma; pharmacodynamics; anemia; nausea; thrombocytopenia; vomiting; relapse; dexamethasone; drug effect; oncology; febrile neutropenia; fever; hyperglycemia; pneumonia; drug cost; hypokalemia; hyponatremia; insomnia; patient care; plasma cell; mental disease; sepsis; maximum plasma concentration; drug metabolism; half life time; tumor suppressor protein; drug dose regimen; epistaxis; upper respiratory tract infection; pharmacology; blurred vision; carfilzomib; hematology; clinical trial (topic); nuclear export; exportin 1; urinary excretion; body weight loss; human; priority journal; volume of distribution; clinical pharmacy; selinexor
Journal Title: Annals of Pharmacotherapy
Volume: 54
Issue: 6
ISSN: 1060-0280
Publisher: Sage Publications  
Date Published: 2020-06-01
Start Page: 577
End Page: 582
Language: English
DOI: 10.1177/1060028019892643
PUBMED: 31793336
PROVIDER: scopus
DOI/URL:
Notes: Review -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Michael Buege
    3 Buege
  2. Jennifer S Orozco
    4 Orozco